← Back to Treatments
🏅 FDA Orphan Designation

Megace

Megestrol acetate

Manufacturer: Bristol-Myers Squibb Pharmaceutical Research Institute

Indicated for:
Aicardi-Goutières syndromeOrphanOBSOLETE: Syndromic ichthyosis associated with ocular featuresAnti-neutrophil cytoplasmic antibody-associated vasculitisNLRP3-associated autoinflammatory disease

FDA-Approved Indications (4)

Aicardi-Goutières syndromeOrphan Designation

Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.

indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS)

Population: patients with AIDS

indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS)

Population: patients with AIDS

indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS)

Population: patients with AIDS

Indications & Usage

INDICATIONS AND USAGE Megestrol acetate oral suspension, USP is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

💙 Support Programs

View all →
Megace
Bristol-Myers Squibb Pharmaceutical Research Institute
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.